Zhang Jian, Shin Meong Cheol, Yang Victor C
Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnosis School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.
Pharm Res. 2014 Mar;31(3):579-92. doi: 10.1007/s11095-013-1182-5. Epub 2013 Sep 25.
A novel PEGylated and heparinized magnetic iron oxide nano-platform (DNPH) was synthesized for simultaneous magnetic resonance imaging (MRI) and tumor targeting.
Starch-coated magnetic iron oxide nanoparticles ("D") were crosslinked, aminated (DN) and then simultaneously PEGylated and heparinized with different feed ratios of PEG and heparin (DNPH1-4). DNPH products were characterized by Fourier transform infrared spectroscopy (FTIR), transmission electron microscopy (TEM) and superconducting quantum interference device (SQUID). The magentic targeting of DNPH3, with appropriate amounts of conjugated PEG and heparin, in a mouse 9L-glioma subcutaneous tumor model was confirmed by magnetic resonance imaging (MRI)/electron spin resonance (ESR).
DNPH3 showed long circulating properties in vivo (half-life >8 h, more than 60-fold longer than that of parent D) and low reticuloendothelial system (RES) recognition in liver and spleen. Protamine, a model cationic protein, was efficiently loaded onto DNPH3 with a maximum loading content of 26.4 μg/mg Fe. Magnetic capture of DNPH3 in tumor site with optimized conditions (I.D. of 12 mg/kg, targeting time of 45 min) was up to 29.42 μg Fe/g tissue (12.26% I.D./g tissue).
DNPH3 showed the potential to be used as a platform for cationic proteins for simultaneous tumor targeting and imaging.
合成一种新型的聚乙二醇化和肝素化磁性氧化铁纳米平台(DNPH),用于同时进行磁共振成像(MRI)和肿瘤靶向。
淀粉包被的磁性氧化铁纳米颗粒(“D”)经交联、胺化(DN),然后用不同比例的聚乙二醇(PEG)和肝素同时进行聚乙二醇化和肝素化(DNPH1 - 4)。通过傅里叶变换红外光谱(FTIR)、透射电子显微镜(TEM)和超导量子干涉装置(SQUID)对DNPH产物进行表征。通过磁共振成像(MRI)/电子自旋共振(ESR)证实了具有适量共轭PEG和肝素的DNPH3在小鼠9L胶质瘤皮下肿瘤模型中的磁靶向性。
DNPH3在体内显示出长循环特性(半衰期>8小时,比母体D长60多倍),并且在肝脏和脾脏中的网状内皮系统(RES)识别率较低。鱼精蛋白,一种典型的阳离子蛋白,以最大负载量26.4μg/mg Fe高效负载到DNPH3上。在优化条件下(剂量为12mg/kg,靶向时间为45分钟),DNPH3在肿瘤部位的磁捕获量高达29.42μg Fe/g组织(12.26%剂量/g组织)。
DNPH3显示出作为阳离子蛋白平台用于同时进行肿瘤靶向和成像的潜力。